Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA. Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335, 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Young AC, Craven RA, Cohen D et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin. Cancer Res.15(24), 7582–7592 (2009).
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel–Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med.349, 419–421 (2003).
   PubMed Web of Science ®Google Scholar
• Rini BI. Vascular endothelial growth factor targeted therapy in metastatic renal cell carcinoma. Cancer115, 2306–2312 (2009).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis I, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. doi/10.1200/JCO.2009.23.9764 (2010) (Epub ahead of print).
   Google Scholar
• Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol.5(9), 1335–1348 (2009).
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhong W. Tumor derived lymphangiogenic factors and lymphatic metastases. Biomed. Pharmacother.61, 534–539 (2007).
   PubMedGoogle Scholar
• Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol.6, 395–404 (2009).
   PubMed Web of Science ®Google Scholar
• Harris PA, Cheung M, Hunter RN et al. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR-2 kinase inhibitors. J. Med. Chem.48, 1610–1619 (2005).
   PubMed Web of Science ®Google Scholar
• Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2 pyrimidinyl]amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem.51, 4632–4640 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther.6(7), 2012–2021 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27, 1–9 (2009).
   PubMedGoogle Scholar
• Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer101, 1717–1723 (2009).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin. Cancer Res.15, 4220–4227 (2009).
   PubMed Web of Science ®Google Scholar
• Votrient™: full prescribing information, October (2009).
   Google Scholar
• Tan AR, Jones SF, Dowlati A et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3552).
   Google Scholar
• Suttle B, Jones SF, Dowlati A et al. Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034). J. Clin. Oncol.2007 ASCO Annual Meeting Proceedings18S(20 Suppl.), 14118 (2007).
   Google Scholar
• Brady J, Middelton M, Midgley RS et al. A Phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer. J. Clin. Oncol.15s(Suppl.), 27 (2009) (Abstract 4133).
   Google Scholar
• Frentzas SN, Groves MD, Barriuso J et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study. J. Clin. Oncol.15s(Suppl.), 27 (2009) (Abstract 2040).
   Google Scholar
• Dejonge M, Savage S, Verweij J et al. A Phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J. Clin. Oncol.2006 ASCO Annual Meeting Proceedings Part I.18S(20 Suppl.), 3088 (2006).
   Google Scholar
• Feldman D, Baum M, Ginsberg M et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 1432–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia JA, Cooney MM et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res.15(19), 6277–6283 (2009).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels JH et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 475–480 (2010).
   Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20, 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• IMS MIDAS (IMS Health) (2009).
   Google Scholar
• Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27, 4462–4468 (2009).
   PubMed Web of Science ®Google Scholar
• Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoima reveals inactivation of histone modifying genes. Nature DOI: 10.1038/nature08672 (2010) (Epub ahead of print).
   Google Scholar
• Bukowski RM, Yasthan U, Kirkpatrick P. Pazopanib. Nat. Rev. Drug Discov.9, 1–2 (2010).
   Google Scholar